Investig Clin Urol.  2017 Jul;58(4):271-280. 10.4111/icu.2017.58.4.271.

Mounting resistance of uropathogens to antimicrobial agents: A retrospective study in patients with chronic bacterial prostatitis relapse

• Stamatiou
• Pierris N

• KMID: 2410295
• DOI: http://doi.org/10.4111/icu.2017.58.4.271

Abstract

PURPOSE
Despite recent progress in the management of chronic bacterial prostatitis (CBP), many cases relapse. Increased drug resistance patterns of responsible bacteria have been proposed as the most probable causative factor. Driven by the limited number of previous studies addressing this topic, we aimed to study whether antibiotic resistance increases in patients with CBP when relapse occurs. A secondary aim of this study was to determine the resistance patterns of responsible bacteria from patients with CBP.
MATERIALS AND METHODS
The study material consisted of bacterial isolates from urine and/or prostatic secretions obtained from patients with CBP. Bacterial identification was performed by using the Vitek 2 Compact system and susceptibility testing was performed by disc diffusion and/or the Vitek 2 system. Interpretation of susceptibility results was based on Clinical and Laboratory Standards Institute guidelines.
RESULTS
A total of 253 samples from patients diagnosed with CBP for the first time (group A) and 137 samples from relapsing patients with a history of CBP and previous antibiotic treatment (group B) were analyzed. A significant reduction in bacterial resistance to the less used antibiotics (TMP-SMX, tetracyclines, aminoglycosides, penicillins, and macrolides) was noted. An increase in resistance to quinolones of many bacteria that cause CBP was also noted with the increase in resistance of enterococcus strains being alarming.
CONCLUSIONS
Comparison of the resistance profile of CBP-responsible bacteria between samples from first-time-diagnosed patients and samples from relapsing patients revealed notable differences that could be attributed to previous antibiotic treatment.

Keyword

Drug resistance; Infection; Prostatitis

MeSH Terms

Aminoglycosides
Anti-Bacterial Agents
Anti-Infective Agents*
Bacteria
Diffusion
Drug Resistance
Drug Resistance, Microbial
Enterococcus
Humans
Penicillins
Prostatitis*
Quinolones
Recurrence*
Retrospective Studies*
Tetracyclines
Aminoglycosides
Anti-Bacterial Agents
Anti-Infective Agents
Penicillins
Quinolones
Tetracyclines

Reference

1. Nickel JC. Perplexing problem of persistently painful prostatitis. Rev Urol. 1999; 1:160–169. PMID: 16985790.

2. Lobel B, Rodriguez A. Chronic prostatitis: what we know, what we do not know, and what we should do! World J Urol. 2003; 21:57–63. PMID: 12774173.

3. Naber KG. Management of bacterial prostatitis: what's new? BJU Int. 2008; 101(Suppl 3):7–10. PMID: 18307679.

4. Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis. 2007; 44:280–286. PMID: 17173232.

5. Stamatiou K, Karageorgopoulos DE. A prospective observational study of chronic prostatitis with emphasis on epidemiological and microbiological features. Urologia. 2013; 80:225–232. PMID: 23813288.

6. Spînu D, Mischianu D, Surcel M, Huică R, Munteanu A, Pîrvu I, et al. Immunological investigations in prostatic pathology--a prospective study. Roum Arch Microbiol Immunol. 2014; 73:51–55. PMID: 25518571.

7. Bartoletti R, Cai T, Nesi G, Albanese S, Meacci F, Mazzoli S, et al. The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study. World J Urol. 2014; 32:737–742. PMID: 23918259.

8. Mazzoli S. Conventional bacteriology in prostatitis patients: microbiological bias, problems and epidemiology on 1686 microbial isolates. Arch Ital Urol Androl. 2007; 79:71–75. PMID: 17695412.

9. Wagenlehner FM, Weidner W, Pilatz A, Naber KG. Urinary tract infections and bacterial prostatitis in men. Curr Opin Infect Dis. 2014; 27:97–101. PMID: 24253463.

10. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010; 74:417–433. PMID: 20805405.

11. Hennessy TW, Petersen KM, Bruden D, Parkinson AJ, Hurlburt D, Getty M, et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: a controlled intervention trial in rural Alaska. Clin Infect Dis. 2002; 34:1543–1550. PMID: 12032887.

12. Clark L. Antibiotic resistance: a growing and multifaceted problem. Br J Nurs. 2000; 9:225–230. PMID: 11033641.

13. Wright GD. The origins of antibiotic resistance. Handb Exp Pharmacol. 2012; (211):13–30. PMID: 23090593.

14. Schulz zur Wiesch P, Engelstädter J, Bonhoeffer S. Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemother. 2010; 54:2085–2095. PMID: 20176903.

15. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother. 2002; 46:1204–1211. PMID: 11959546.

16. Eisenstein B, Sparling PF. Mutations to increased antibiotic sensitivity in naturally-occurring gonococci. Nature. 1978; 271:242–244. PMID: 414141.

17. Yap PS, Lim SH, Hu CP, Yiap BC. Combination of essential oils and antibiotics reduce antibiotic resistance in plasmid-conferred multidrug resistant bacteria. Phytomedicine. 2013; 20:710–713. PMID: 23537749.

18. Panagopoulos P, Antoniadou A, Kanellakopoulou K, Tsiodras S, Katsarolis I, Papadopoulos A, et al. Fluoroquinolone treatment of chronic bacterial prostatitis: a prospective cohort study. J Chemother. 2009; 21:317–321. PMID: 19567353.

19. Cai T, Mazzoli S, Meacci F, Boddi V, Mondaini N, Malossini G, et al. Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. J Microbiol. 2011; 49:448–454. PMID: 21717331.

20. van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, et al. Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med. 2005; 171:480–487. PMID: 15516540.

21. Lachant DJ, Apostolakos M, Pietropaoli A. Methicillin resistant Staphylococcus aureus prostatic abscess with bacteremia. Case Rep Infect Dis. 2013; 2013:613961. PMID: 24455341.

22. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014; 22:438–445. PMID: 24842194.

23. Guillemot D, Varon E, Bernède C, Weber P, Henriet L, Simon S, et al. Reduction of antibiotic use in the community reduces the rate of colonization with penicillin G-nonsusceptible Streptococcus pneumoniae. Clin Infect Dis. 2005; 41:930–938. PMID: 16142656.

24. Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015; 34:877–886. PMID: 25630538.

25. David RD, DeBlieux PM, Press R. Rational antibiotic treatment of outpatient genitourinary infections in a changing environment. Am J Med. 2005; 118(Suppl 7A):7S–13S.

26. Masterton RG. Antibiotic de-escalation. Crit Care Clin. 2011; 27:149–162. PMID: 21144991.

27. Magri V, Montanari E, Škerk V, Markotić A, Marras E, Restelli A, et al. Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Androl. 2011; 13:819–827. PMID: 21765442.

28. Stamatiou K, Koritsiadis G. The clinical efficacy of short term minocycline administration in patients with chronic bacterial prostatitis from gram - positive microorganisms: a prospective, pilot study. Hell Urol. 2015; 27:38–46.

29. Vinarov AZ, Stojlov SV, Kozyrev SV, Surikov VN, Chaban AV, Kurbatov DG, et al. Doxycycline (UNIDOX SOLUTAB®) and/or josamycin (WILPRAFEN®) in treatment of patients with prostatitis in real clinical practice. results of the taurus observational program. Urologiia. 2015; (3):75–78. 80–83. PMID: 26390565.

30. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010; 50:1641–1652. PMID: 20459324.